1. Home
  2. XMTR vs PBLS Comparison

XMTR vs PBLS Comparison

Compare XMTR & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xometry Inc.

XMTR

Xometry Inc.

HOLD

Current Price

$93.09

Market Cap

4.2B

Sector

Technology

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$37.38

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XMTR
PBLS
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
3.6B
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
XMTR
PBLS
Price
$93.09
$37.38
Analyst Decision
Buy
Analyst Count
10
0
Target Price
$58.60
N/A
AVG Volume (30 Days)
803.3K
388.3K
Earning Date
05-07-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
26.95
N/A
EPS
N/A
N/A
Revenue
$686,631,000.00
N/A
Revenue This Year
$23.76
N/A
Revenue Next Year
$18.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.87
N/A
52 Week Low
$35.86
$25.56
52 Week High
$106.08
$36.95

Technical Indicators

Market Signals
Indicator
XMTR
PBLS
Relative Strength Index (RSI) 53.13 68.83
Support Level $88.52 $26.42
Resistance Level $98.55 N/A
Average True Range (ATR) 4.67 2.30
MACD 0.33 0.31
Stochastic Oscillator 77.15 95.45

Price Performance

Historical Comparison
XMTR
PBLS

About XMTR Xometry Inc.

Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: